JP2024502954A5 - - Google Patents

Info

Publication number
JP2024502954A5
JP2024502954A5 JP2023539784A JP2023539784A JP2024502954A5 JP 2024502954 A5 JP2024502954 A5 JP 2024502954A5 JP 2023539784 A JP2023539784 A JP 2023539784A JP 2023539784 A JP2023539784 A JP 2023539784A JP 2024502954 A5 JP2024502954 A5 JP 2024502954A5
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
cells
independently
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023539784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502954A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012941 external-priority patent/WO2022159463A1/en
Publication of JP2024502954A publication Critical patent/JP2024502954A/ja
Publication of JP2024502954A5 publication Critical patent/JP2024502954A5/ja
Pending legal-status Critical Current

Links

JP2023539784A 2021-01-20 2022-01-19 ナノ材料 Pending JP2024502954A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163139734P 2021-01-20 2021-01-20
US63/139,734 2021-01-20
PCT/US2022/012941 WO2022159463A1 (en) 2021-01-20 2022-01-19 Nanomaterials

Publications (2)

Publication Number Publication Date
JP2024502954A JP2024502954A (ja) 2024-01-24
JP2024502954A5 true JP2024502954A5 (cg-RX-API-DMAC10.html) 2025-01-24

Family

ID=82549752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023539784A Pending JP2024502954A (ja) 2021-01-20 2022-01-19 ナノ材料

Country Status (10)

Country Link
US (2) US12059477B2 (cg-RX-API-DMAC10.html)
EP (1) EP4281050A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024502954A (cg-RX-API-DMAC10.html)
KR (1) KR20230131863A (cg-RX-API-DMAC10.html)
CN (1) CN116761888A (cg-RX-API-DMAC10.html)
AU (1) AU2022210313A1 (cg-RX-API-DMAC10.html)
CA (1) CA3203742A1 (cg-RX-API-DMAC10.html)
IL (1) IL303846A (cg-RX-API-DMAC10.html)
MX (1) MX2023008333A (cg-RX-API-DMAC10.html)
WO (1) WO2022159463A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600208B2 (ja) 2019-07-29 2024-12-16 ジョージア テック リサーチ コーポレイション 拘束された脂質を含むナノ材料およびその使用
CN115175894B (zh) 2020-01-09 2024-09-06 盖德治疗有限责任公司 纳米材料
CA3203741A1 (en) * 2021-01-20 2022-07-28 Beam Therapeutics Inc. Nanomaterials comprising an ionizable lipid
CN116761888A (zh) 2021-01-20 2023-09-15 比姆医疗股份有限公司 纳米材料
EP4281080A4 (en) 2021-01-20 2025-09-24 Beam Therapeutics Inc NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
EP4540222A1 (en) 2022-07-20 2025-04-23 Beam Therapeutics Inc. Nanomaterials comprising triols
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110977A (en) 1990-02-14 1992-05-05 Eastman Kodak Company Ester-containing quaternary ammonium salts as adhesion improving toner charge agents
EP1021549A2 (en) 1997-09-19 2000-07-26 Sequitur, Inc. SENSE mRNA THERAPY
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
WO2016187531A1 (en) 2015-05-21 2016-11-24 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
KR102710962B1 (ko) 2017-07-04 2024-09-27 주식회사 인투셀 절단성 링커를 포함하는 화합물 및 이들의 용도
JP7449231B2 (ja) 2017-10-30 2024-03-13 ジョージア テック リサーチ コーポレーション 組織送達用材料の多重化解析
US11622942B2 (en) 2017-11-14 2023-04-11 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof
MX2021003455A (es) 2018-10-02 2021-09-21 Intellia Therapeutics Inc Lípidos con amina ionizables.
CN119285480A (zh) 2018-12-05 2025-01-10 英特利亚治疗股份有限公司 改性的胺脂质
EP3911302B1 (en) 2019-01-17 2025-09-10 Georgia Tech Research Corporation Drug delivery systems containing oxidized cholesterols
EP3924479A4 (en) 2019-02-13 2023-01-25 Beam Therapeutics, Inc. ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
US20220233459A1 (en) 2019-06-05 2022-07-28 Guide Therapeutics, Inc. Analysis of materials for tissue delivery
EP4004207A4 (en) 2019-07-29 2023-08-23 Georgia Tech Research Corporation OLIGONUCLEOTIDE ANTAGONISTS FOR RNA-GUIDED GENO EDITING
JP7600208B2 (ja) 2019-07-29 2024-12-16 ジョージア テック リサーチ コーポレイション 拘束された脂質を含むナノ材料およびその使用
JP7699128B2 (ja) 2019-12-06 2025-06-26 ガイド セラピューティクス,エルエルシー ナノマテリアル
CN115175894B (zh) 2020-01-09 2024-09-06 盖德治疗有限责任公司 纳米材料
EP4262817A4 (en) 2020-12-21 2025-03-12 Beam Therapeutics Inc. NANOMATERIALS WITH ACETALS
JP2024508347A (ja) 2020-12-21 2024-02-27 ビーム セラピューティクス インク. エステル結合アセタールを含むナノ材料
JP2024505327A (ja) 2020-12-21 2024-02-06 ビーム セラピューティクス インク. 炭酸塩を含むナノ材料
AU2022210299A1 (en) 2021-01-20 2023-06-29 Beam Therapeutics Inc. Ionizable lipids for nanomaterials
EP4281080A4 (en) 2021-01-20 2025-09-24 Beam Therapeutics Inc NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
CN116761888A (zh) 2021-01-20 2023-09-15 比姆医疗股份有限公司 纳米材料
CA3203741A1 (en) 2021-01-20 2022-07-28 Beam Therapeutics Inc. Nanomaterials comprising an ionizable lipid
CA3241488A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Ionizable amine lipids and lipid nanoparticles
WO2023121971A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising tetravalent lipid compounds
WO2023121970A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Ionizable amine and ester lipids and lipid nanoparticles
WO2023121964A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising disulfides
WO2023121965A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterial comprising diamines

Similar Documents

Publication Publication Date Title
JP2024505449A5 (cg-RX-API-DMAC10.html)
JP2024502948A5 (cg-RX-API-DMAC10.html)
JP2024503441A5 (cg-RX-API-DMAC10.html)
JP2025501731A5 (cg-RX-API-DMAC10.html)
JP2025500824A5 (cg-RX-API-DMAC10.html)
JP5813778B2 (ja) トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド(iro)化合物
EP2996472B1 (en) Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
JP2024505327A (ja) 炭酸塩を含むナノ材料
CN112805294A (zh) 用于核酸递送的叔氨基脂化的阳离子肽
JP2018537528A (ja) Nlrp3遺伝子発現を阻害するための組成物およびその使用
JP2019504002A5 (cg-RX-API-DMAC10.html)
AU2009302468A1 (en) Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
JP2024535004A (ja) イオン化可能な脂質その調製および遺伝子送達における使用
CN117440834A (zh) 核糖核酸的体内递送用组合物及其制备方法
CN116963729A (zh) 包括可电离脂质的纳米材料
CN118421594A (zh) 包含突变kras序列和脂质的化合物及其用途
CN116615472A (zh) 聚合物缀合的脂质化合物和脂质纳米颗粒组合物
JP2024503976A5 (cg-RX-API-DMAC10.html)
BR112015016420B1 (pt) Composto de oligonucleotídeo imunorregulatório, composição farmacêutica e uso do composto iro ou da composição farmacêutica
JP2018150239A (ja) β2GPI遺伝子発現抑制RNAi医薬組成物
WO2024183821A1 (zh) 可离子化脂质分子及其制备方法和应用
TWI876778B (zh) 用於傳遞核酸的基於環烷的脂質化合物以及包括其之脂質奈米粒子
WO2018084168A1 (ja) 皮膚線維症処置剤
Gao et al. Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy
US11802139B2 (en) Pharmaceutical composition and the use thereof in the treatment of autoimmune diseases